Filtered By:
Cancer: Leukemia

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 341 results found since Jan 2013.

Progress against cancer? Let ' s think about it.
It is difficult to pick up a newspaper these days without reading an article proclaiming progress in the field of cancer research. Here is an example, taken from an article posted on the MedicineNet site (1). The lead-off text is: " Statistics (released in 1997) show that cancer patients are living longer and even " beating " the disease. Information released at an AMA sponsored conference for science writers, showed that the death rate from the dreaded disease has decreased by three percent in the last few years. In the 1940s only one patient in four survived on the average. By the 1960s, that figure was up to one in thre...
Source: Specified Life - March 25, 2016 Category: Information Technology Tags: cancer cancer cure cancer statistics cancer treatments orphan diseases progress in cancer research rare diseases Source Type: blogs

Scientific Misconduct at Prestigious Research Centers
On January 23, 2009, the Office of Research Integrity made public their findings of scientific misconduct concerning a doctor who fabricated data for several grants projects funded by the NIH (1). The doctor was a former graduate student in the Department of Pathology, Harvard Medical School, a former research fellow and Instructor of Pathology, at Brigham and Women's Hospital in Boston, a former postdoctoral fellow in the Department of Biology, at the California Institute of Technology, and a former Associate Professor in the Department of Biology and the Center for Cancer Research at the Massachusetts Institute of Techno...
Source: Specified Life - March 24, 2016 Category: Information Technology Tags: ethics fraud Karolinska Institute ORI scientific misconduct Source Type: blogs

Don’t Let the Talking Points Fool You: It’s All About the Risk Pool
Most people are healthy most of the time, and as a consequence, health care expenditures are heavily concentrated in a small share of the population: about 50 percent of the health care spending in a given year by those below age 65 is attributable to just 5 percent of the nonelderly population. The lowest spending half of the population accounts for only about 3.5 percent of health care spending in a year. Deciding how much of total health care expenditures should be shared across the population and how to share it is the fundamental conundrum of health care policy. There is more risk pooling the larger the share of healt...
Source: Health Affairs Blog - March 15, 2016 Category: Health Management Authors: Linda Blumberg and John Holahan Tags: Costs and Spending Equity and Disparities Featured Insurance and Coverage Medicaid and CHIP Medicare community rating Employer-Sponsored Insurance experience rating guaranteed issue and renewal health savings accounts high-risk pools Source Type: blogs

Don ’t Believe These 3 Myths About Living With Cancer
When people find out that I have stage 4 terminal breast cancer, they have varied reactions. Some are saddened and compassionate, some are concerned and curious, and others, because of their own fears, need to find an explanation — a way to feel in control. This often leads to myths about living with cancer that can be insulting to those of us who are battling the disease. Let’s examine the truth behind three of these myths: Myth #1: If you are a positive person with a great attitude, you won’t get cancer. My father, mother, and niece all battled cancer. My parents were anything but people who gave in or gave up. Th...
Source: Life with Breast Cancer - March 8, 2016 Category: Cancer & Oncology Authors: Kathy-Ellen Kups, RN Tags: Breast Cancer Nutrition Risk Factors treatment Source Type: blogs

Don’t Believe These 3 Myths About Living With Cancer
When people find out that I have stage 4 terminal breast cancer, they have varied reactions. Some are saddened and compassionate, some are concerned and curious, and others, because of their own fears, need to find an explanation — a way to feel in control. This often leads to myths about living with cancer that can be insulting to those of us who are battling the disease. Let’s examine the truth behind three of these myths: Myth #1: If you are a positive person with a great attitude, you won’t get cancer. My father, mother, and niece all battled cancer. My parents were anything but people who gave in or gave up. Th...
Source: Life with Breast Cancer - March 8, 2016 Category: Cancer & Oncology Authors: Kathy-Ellen Kups, RN Tags: Breast Cancer Nutrition Risk Factors treatment Source Type: blogs

The Health Care Question We Need to Be Asking the Candidates
By ANEES CHAGAR, MD As many of the Republican and Democratic presidential candidates lament the high cost of healthcare and put forth how they aim to make it more cost effective, few have focused on the impact of out-of-pocket costs specifically for cancer patients. They should. One in every two men and one in every three women will get cancer at some point over their lifetime. As the U.S. population and American lifespans increase, this toll will have major financial ramification for everyone. When fighting against the disease, cancer patients are often at the mercy of the pharmaceutical industry. Given Pfizer’s r...
Source: The Health Care Blog - February 28, 2016 Category: Consumer Health News Authors: John Irvine Tags: THCB Anees Chagar Source Type: blogs

Cancer and the Politics of Moonshots
By ANEES CHAGPAR, MD As many of the Republican and Democratic presidential candidates lament the high cost of healthcare and put forth how they aim to make it more cost effective, few have focused on the impact of out-of-pocket costs specifically for cancer patients. They should. One in every two men and one in every three women will get cancer at some point over their lifetime. As the U.S. population and American lifespans increase, this toll will have major financial ramification for everyone. When fighting against the disease, cancer patients are often at the mercy of the pharmaceutical industry. Given Pfizer’s ...
Source: The Health Care Blog - February 28, 2016 Category: Consumer Health News Authors: John Irvine Tags: THCB Anees Chagar Source Type: blogs

Makayla Sault’s mother: Racism, trust, and science-based medicine
One of the recurring topics I write about is, of course, cancer quackery. It goes right back to the very beginning of this blog, to my very earliest posts more than 11 years ago. Over the years I’ve covered more cases than I can remember of patients relying on quackery instead of real medicine. In…
Source: Respectful Insolence - January 18, 2016 Category: Surgery Authors: Orac Tags: Cancer Complementary and alternative medicine History Politics Quackery Religion Science Skepticism/critical thinking aborigine acute lymphoblastic leukemia Brian Clement Canada chemotherapy First Nations Justice Gethin Edward Source Type: blogs

What They Really Think of Us (Swiss Version) - Novartis CEO Would Not Commit to Changing Company Behavior After Latest of Multiple Legal Settlements
The huge corporations which now dominate global health care are creating amazing records of repeated ethical misadventures.  We last discussed multinational Swiss based pharmaceutical manufacturer Novartis' escapades in early 2014.   Since then, the legal settlements and other legal findings just keep on coming, capped with a big one in late October, 2015.We will summarize them in chronological order.Japanese Health, Labor and Welfare Ministry Found that Novartis Concealed Serious Adverse EffectsIn August, 2014, per the Japan Times, but apparently not reported widely outside of that country.Novartis Pharma K...
Source: Health Care Renewal - November 5, 2015 Category: Health Management Tags: corporate integrity agreement deception Express Scripts impunity kickbacks legal settlements Novartis Switzerland what they really think of us Source Type: blogs

CME Back to the Future
Conclusion As has been made clear from many years of research and education, science is constantly changing, and advocating for less research and fewer new drugs, as the authors of the "Slippery Slope" series are wont to do, is a dangerous pastime. We cannot use yesterday's science on today's problems. Medical research and continuing medical education are two important factors in making sure our healthcare providers are as up-to-date and efficient as possible.   The CME Coalition has issued a strong response to the MedPage Today/Milwaukee Journal Sentinel Slippery Slope articles and gracefully MedPage today publishe...
Source: Policy and Medicine - October 27, 2015 Category: American Health Authors: Policy and Medicine Writing Staff Source Type: blogs

Marcia Angell writes
By Marcia AngellIn 1953, a new drug was released by Burroughs Wellcome, a pharmaceutical company based in London. Pyrimethamine, as the compound was named, was originally intended to fight malaria after the microorganisms that cause the disease developed resistance to earlier therapies. The drug was used against malaria for several decades, often in combination with other compounds. It ’s mostly used now to treat toxoplasmosis, a parasitic infection that can be life-threatening in people whose immune systems are suppressed, for example, by HIV/​AIDS or cancer.More than 40 years later, Burroughs Wellcome merged with the...
Source: PharmaGossip - October 4, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs

The Section 1557 Regulation: What’s Missing, And How We Can Include It
Kristin Agar, a 63-year-old social worker, was diagnosed with lupus in 2008, a rare disease in which the body’s own immune system can cause serious damage to the kidneys, brain, skin, and joints. Unfortunately, despite having insurance coverage, Kristin has found that the drug she needs to treat her lupus is unaffordable. All around the United States, Kristin joins other patients with chronic conditions like HIV, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, and Leukemia, who are having trouble paying for their medications. In June, Robert Restuccia and I wrote a Health Affairs Blog post showing that discrimi...
Source: Health Affairs Blog - September 21, 2015 Category: Health Management Authors: Douglas Jacobs Tags: Costs and Spending Drugs and Medical Technology Equity and Disparities Following the ACA Insurance and Coverage Long-term Services and Supports Payment Policy Population Health Public Health Americans With Disabilities Act chronic dise Source Type: blogs

Considering Klotho Delivery as a Means to Reduce Age-Related Stem Cell Decline
Today I'll point out an open access paper on the longevity-related gene klotho. Some researchers see therapies to adjust levels of the klotho protein produced from this genetic blueprint as a possible way to slow some of the effects of aging, particularly those connected to regeneration and stem cell activity. Work on this is slow-moving and painstaking, as for any similar approaches. Yet a fairly large section of the medical research community is now devoted to at least partial and temporary restoration of tissue maintenance by stem cells in the old. A good fraction of the frailty and failure of aging results not just fr...
Source: Fight Aging! - September 14, 2015 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Getting (to the Value) of Value In Health Care
By SUSAN DENTZER How would you judge the value of your health care? A longstanding definition of treatment holds that value is the health outcomes achieved for the dollars spent. Yet behind that seemingly simple formula lies much complexity. Think about it: Calculating outcomes and costs for treating a short-term acute condition, such as a child’s strep throat, may be easy. But it’s far harder to pinpoint value in a long-term serious illness such as advanced cancer, in which both both the outcomes and costs of treating a given individual—let alone a population with a particular cancer—may be unknown for years. And ...
Source: The Health Care Blog - September 11, 2015 Category: Consumer Health News Authors: John Irvine Tags: THCB PCORI Physicians Robert Wood Johnson Theranos Value value-based care Source Type: blogs